SARS-CoV-2 Nucleocapsid antibody

Catalog No. ABIN6952432

Cited in 12+ publications. This anti-SARS-CoV-2 Nucleocapsid antibody is a Mouse Monoclonal antibody detecting SARS-CoV-2 Nucleocapsid in ELISA, WB and IF. Suitable for SARS Coronavirus-2 (SARS-CoV-2).

Quick Overview for SARS-CoV-2 Nucleocapsid antibody (ABIN6952432)

Target: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Reactivity: SARS Coronavirus-2 (SARS-CoV-2)

Host: Mouse

Clonality: Monoclonal

Conjugate: This SARS-CoV-2 Nucleocapsid antibody is un-conjugated

Application: ELISA, Western Blotting (WB), Immunofluorescence (IF)

Clone: 3851

Product Details anti-SARS-CoV-2 Nucleocapsid Antibody

Specificity: Specific for the nucleoprotein of the SARS virus.

Purification: SARS-CoV-2 (COVID-19, 2019-nCoV) Nucleoprotein antibody is purified from ascites fluid or culture medium by protein A chromoatography or sequential differential precipitations.

Isotype: IgG2b

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: phosphate saline buffer (0.01M, pH 7.2) containing 0.1 % sodium azide preservative. No stabilizing proteins have been added.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: antibody can be stored at -20°C, stable for one year.

Expiry Date: 12 months

References for anti-SARS-CoV-2 Nucleocapsid antibody (ABIN6952432)

Mirabelli, Bragazzi Cunha, Wotring, Sherman, El Saghir, Harder, Kretzler, Sexton, Emmer, Wobus: "ARF6 is a host factor for SARS-CoV-2 infection in vitro." in: The Journal of general virology, Vol. 104, Issue 6, (2023) (PubMed).

Qiao, Wotring, Zhang, Jiang, Xiao, Watt, Gattis, Scandalis, Freier, Zheng, Pretto, Ellison, Swayze, Guo, Sexton, Chinnaiyan: "Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection." in: PloS one, Vol. 18, Issue 2, pp. e0281281, (2023) (PubMed).

Qiao, Wotring, Zheng, Zhang, Zhang, Jiang, Pretto, Eyunni, Parolia, He, Cheng, Cao, Wang, Su, Ellison, Wang, Qin, Yan, Zhou, Ma, Sexton, Chinnaiyan: "Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Issue 30, pp. e2221809120, (2023) (PubMed).

Wotring, Fursmidt, Ward, Sexton: "Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern." in: Journal of dairy science, (2022) (PubMed).

Sherman, Mirabelli, Tang, Khan, Leix, Kennedy, Graham, Willer, Tai, Sexton, Wobus, Emmer: "Identification of cell type specific ACE2 modifiers by CRISPR screening." in: PLoS pathogens, Vol. 18, Issue 3, pp. e1010377, (2022) (PubMed).

Mirabelli, Sherman, Wotring, El Saghir, Bragazzi Cunha, Harder, Sexton, Emmer, Wobus: "ARF6 is an important host factor for SARS-CoV-2 infection in vitro." in: bioRxiv : the preprint server for biology, (2022) (PubMed).

Wotring, McCarty, Shafiq, Zhang, Nguyen, Meyer, Fursmidt, Mirabelli, Clasby, Wobus, OMeara, Sexton: "In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment." in: bioRxiv : the preprint server for biology, (2022) (PubMed).

Yao, Subedi, Liu, Khalasawi, Pretto-Kernahan, Wotring, Wang, Yin, Jiang, Fu, Dimitrion, Li, Veenstra, Yi, McKinnon, McKinnon, Sexton, Zhou, Mi: "Surface translocation of ACE2 and TMPRSS2 upon TLR4/7/8 activation is required for SARS-CoV-2 infection in circulating monocytes." in: Cell discovery, Vol. 8, Issue 1, pp. 89, (2022) (PubMed).

Wotring, McCarty, Shafiq, Zhang, Nguyen, Meyer, Fursmidt, Mirabelli, Clasby, Wobus, OMeara, Sexton: "In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment." in: Vaccines, Vol. 10, Issue 8, (2022) (PubMed).

Mirabelli, Wotring, Zhang, McCarty, Fursmidt, Pretto, Qiao, Zhang, Frum, Kadambi, Amin, OMeara, Spence, Huang, Alysandratos, Kotton, Handelman, Wobus, Weatherwax, Mashour, OMeara, Chinnaiyan, Sexton: "Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Issue 36, (2021) (PubMed).

Baang, Smith, Mirabelli, Valesano, Manthei, Bachman, Wobus, Adams, Washer, Martin, Lauring: "Prolonged SARS-CoV-2 replication in an immunocompromised patient." in: The Journal of infectious diseases, (2020) (PubMed).

Mirabelli, Wotring, Zhang, McCarty, Fursmidt, Frum, Kadambi, Amin, OMeara, Pretto, Spence, Huang, Alysandratos, Kotton, Handelman, Wobus, Weatherwax, Mashour, OMeara, Sexton: "Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19." in: bioRxiv : the preprint server for biology, (2020) (PubMed).

Target Details for SARS-CoV-2 Nucleocapsid

Target: SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)

Alternative Name: SARS-CoV-2 Nucleocapsid Protein

Target Type: Viral Protein